Article citationsMore>>

GlaxoSmithKline (2012) Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and the Safety of Six Months’ Administration of SB-683699 in Subjects with Relapsing-Remitting Multiple Sclerosis. NCT00395317.

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top